

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.elsevier.com/locate/chnjc](http://www.elsevier.com/locate/chnjc)

Article (Special Issue on Catalysis in Organic Synthesis)

# Diastereo- and enantioselective conjugate addition of $\alpha$ -keto esters to nitroalkenes: Complete switch in the enantioselectivity by tuning the metal center or rigidity of the ligand

Xiangning Chen, Han Zhou, Hanmin Huang\*

State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, Gansu, China



## ARTICLE INFO

## Article history:

Received 15 May 2014

Accepted 15 June 2014

Published 20 January 2015

## Keywords:

Chiral diamine

Conjugate addition

Dual enantioselectivity

Metal center

Rigid ligand

## ABSTRACT

A series of efficient catalytic systems has been developed to control the dual enantioselectivity of the conjugate addition of  $\alpha$ -keto esters to nitroalkenes. The use of the chiral diamine (1*S*,1'*S*)-1,1'-biisoindoline as a chiral ligand with either  $(\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O})$  or  $(\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O})$  as the catalyst provide facile access to the respective enantiomers resulting from the conjugate addition reaction with high levels of enantioselectivity (94% ee vs 93% ee). Furthermore, the use of  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$  as the metal center allowed the enantioselectivity of the conjugate addition reaction to be switched through the tuning of the rigidity of the chiral diamine ligand (94% ee vs 94% ee).

© 2015, Dalian Institute of Chemical Physics, Chinese Academy of Sciences.

Published by Elsevier B.V. All rights reserved.

## 1. Introduction

Asymmetric catalysis represents one of the most powerful and efficient methods for the preparation of enantiopure compounds, and this technique has been applied extensively in the fields of pharmaceutical and biological chemistry, where it has been used to prepare important therapeutic agents and biologically active compounds. In general, both enantiomers of new compounds bearing a stereogenic center are synthesized for applications in biosynthesis and medical chemistry, so that the enantiomer responsible for any observed activity against a specific target can be clearly identified [1–6]. In theory, it should be possible to develop a straightforward approach to both enantiomers using two enantiopure antipodal chiral catalysts and a single prochiral starting material. However, enantiopure chiral ligands with the opposite absolute configurations

are not always readily available or easy to prepare, and can be particularly problematic for ligands derived from naturally available chiral sources such as amino acids, carbohydrates and alkaloids. For this reason, several alternative methods have also been developed to induce a reversal in the enantioselectivity of a reaction by either tuning the reaction conditions (e.g., solvent, temperature and additive) [7–14], using a chiral ligand derived from a single chiral source with a modified subunit [15–20] or changing the metal center of the catalyst [21–29]. One of the most widely used methods for turning the enantioselectivity of a reaction involves effectively tuning the metal center of the catalyst. This approach is particularly useful because of the diverse reactivity profiles of different transition metals.

The catalytic enantioselective conjugate addition of carbon nucleophiles to nitroalkenes has received considerable atten-

\* Corresponding author. Tel: +86-931-4968326; Fax: +86-931-4968129; E-mail: [hmhuang@licp.cas.cn](mailto:hmhuang@licp.cas.cn)

This work was supported by the National Natural Science Foundation of China (21222203, 21172226, and 21133011).

DOI: 10.1016/S1872-2067(14)60199-6 | <http://www.sciencedirect.com/science/journal/18722067> | Chin. J. Catal., Vol. 36, No. 1, January 2015



resulting mixture was stirred at room temperature for 10 h. The solvent was removed under reduced pressure to give the crude product as a residue, which was purified by flash column chromatography over silica gel eluting with a mixture of EtOAc and hexanes (1/40 to 1/20, v/v) to afford the desired product. The dr was obtained by checking the  $^1\text{H}$  NMR of the crude product.

**Method b.** A mixture of chiral diamine **2d** (4.4 mg, 0.011 mmol, 5.5 mol%) and  $\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$  (2.6 mg, 0.010 mmol, 5 mol%) in dry  $\text{CH}_3\text{CN}$  (2.0 mL) was added to a flame-dried young-type tube under an atmosphere of argon atmosphere, and the resulting mixture was stirred at 40 °C for 2 h. The solvent was then removed under vacuum to give the catalyst as a blue grey powder. *tert*-Butyl-2-oxo-4-phenylbutanoate (**4a**) (51.9 mg, 0.22 mmol, 1.1 equiv), (*E*)-(2-nitrovinyl)benzene (**5a**) (29.8 mg, 0.20 mmol, 1.0 equiv), triethylamine (1.5  $\mu\text{L}$ , 0.01 mmol, 5 mol%), and CPME (2.0 mL) were then added sequentially to the dried catalyst under an atmosphere of argon, and the resulting mixture was stirred at room temperature for 16 h. The solvent was then removed under reduced pressure to give the crude product, which was purified by flash column chromatography over silica gel eluting with a mixture of EtOAc and hexanes (1/40 to 1/20, v/v) to afford the desired product. The dr was obtained by checking the  $^1\text{H}$  NMR of the crude product.

**Method c.** A mixture of chiral diamine **3** (0.5 mg, 0.0022 mmol, 1.1 mol%) and  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$  (0.4 mg, 0.0020 mmol, 1 mol%) in dry  $\text{CH}_2\text{Cl}_2$  (2.0 mL) was added to a flame-dried young-type tube under an atmosphere of argon, and the resulting mixture was stirred at 40 °C for 30 min. The solvent was then removed under vacuum to give the catalyst as a blue powder. *tert*-Butyl-2-oxo-4-phenylbutanoate (**4a**) (51.9 mg, 0.22 mmol, 1.1 equiv), (*E*)-(2-nitrovinyl)benzene (**5a**) (29.8 mg, 0.20 mmol, 1.0 equiv), triethylamine (1.5  $\mu\text{L}$ , 0.01 mmol, 5 mol%), and *i*-PrOH (2.0 mL) were then added sequentially to the dried catalyst under an atmosphere of argon, and the resulting mixture was stirred at room temperature for 10 h. The solvent was then removed under reduced pressure to give the crude product as a residue, which was purified by flash column chromatography over silica gel eluting with a mixture of EtOAc and hexanes (1/40 to 1/20, v/v) to afford the desired product. The dr was obtained by checking the  $^1\text{H}$  NMR of the crude product.

### 2.3. Experimental characterization data for diamine ligands

(1*S*,1'*S*)-1,1'-Biisoindoline (**2a**): white solid,  $[\alpha]_{\text{D}}^{20} = +95.0$  (c 0.5,  $\text{CH}_3\text{OH}$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.34–7.35 (m, 2H), 7.24–7.30 (m, 6H), 4.95 (s, 2H), 4.19 (dd,  $J_1 = 13.6$  Hz,  $J_2 = 29.2$  Hz, 4H), 2.21 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  142.5, 141.7, 127.3, 126.9, 122.6, 122.2, 66.3, 52.1. HRMS (ESI) Calcd. for  $\text{C}_{16}\text{H}_{17}\text{N}_2$   $[\text{M}+1]^+$ : 237.1392; Found: 237.1395.

(1*S*,1'*S*)-6,6'-Difluoro-1,1'-biisoindoline (**2b**): white solid,  $[\alpha]_{\text{D}}^{20} = +96.1$  (c 0.155,  $\text{CH}_3\text{OH}$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.16–7.19 (m, 2H), 7.01–7.03 (m, 2H), 6.93–6.97 (m, 2H), 4.88 (s, 2H), 4.17 (dd,  $J_1 = 13.6$  Hz,  $J_2 = 29.2$  Hz, 4H), 2.16 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  161.3 ( $J = 243.0$  Hz), 143.7 ( $J = 8.0$  Hz), 137.8 ( $J = 2.0$  Hz), 123.6 ( $J = 9.0$  Hz), 114.4 ( $J = 23.0$  Hz),

109.3 ( $J = 23.0$  Hz), 66.3 ( $J = 2.0$  Hz), 51.6;  $^{19}\text{F}$  NMR (376 MHz,  $\text{CDCl}_3$ )  $\delta$  -116.3 (s). HRMS (ESI) Calcd. for  $\text{C}_{16}\text{H}_{15}\text{F}_2\text{N}_2$   $[\text{M}+1]^+$ : 273.1198; Found: 273.1201.

(1*S*,1'*S*)-6,6'-Dichloro-1,1'-biisoindoline (**2c**): white solid,  $[\alpha]_{\text{D}}^{20} = +143.3$  (c 0.159,  $\text{CH}_3\text{OH}$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.30 (s, 2H), 7.22 (dd,  $J_1 = 1.6$  Hz,  $J_2 = 8.0$  Hz, 2H), 7.15 (d,  $J = 8.0$  Hz, 2H), 4.88 (s, 2H), 4.13 (dd,  $J_1 = 13.6$  Hz,  $J_2 = 30.0$  Hz, 4H), 2.08 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  143.7, 141.0, 132.8, 127.6, 123.7, 122.5, 66.2, 51.8. HRMS (ESI) Calcd. for  $\text{C}_{16}\text{H}_{15}\text{Cl}_2\text{N}_2$   $[\text{M}+1]^+$ : 305.0607; Found: 305.0609.

(1*S*,1'*S*)-6,6'-Dibromo-1,1'-biisoindoline (**2d**): white solid,  $[\alpha]_{\text{D}}^{20} = +130.2$  (c 0.152,  $\text{CH}_3\text{OH}$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.45 (s, 2H), 7.37 (dd,  $J_1 = 1.6$  Hz,  $J_2 = 8.0$  Hz, 2H), 7.10 (d,  $J = 8.0$  Hz, 2H), 4.87 (s, 2H), 4.14 (dd,  $J_1 = 14.0$  Hz,  $J_2 = 31.2$  Hz, 4H), 2.07 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  144.1, 141.6, 130.5, 125.5, 124.1, 120.8, 66.2, 51.9. HRMS (ESI) Calcd. for  $\text{C}_{16}\text{H}_{15}\text{Br}_2\text{N}_2$   $[\text{M}+1]^+$ : 392.9597; Found: 392.9611.

(4*bS*,10*bS*)-4*b*,5,6,10*b*,11,12-Hexahydrodibenzo[*c,h*][1,5]naphthyridine (**3**): white solid,  $[\alpha]_{\text{D}}^{20} = -115.1$  (c 0.392,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.39–7.41 (m, 2H), 7.22–7.28 (m, 4H), 7.08–7.10 (m, 2H), 4.08 (dd,  $J_1 = 16.0$  Hz,  $J_2 = 75.6$  Hz, 4H), 3.81 (s, 2H), 2.04 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  136.7, 136.4, 130.5, 127.4, 126.7, 125.8, 54.0, 49.2. HRMS (ESI) Calcd. for  $\text{C}_{16}\text{H}_{17}\text{N}_2$   $[\text{M}+1]^+$ : 237.1392; Found: 237.1399.

### 2.4. Experimental characterization data for products

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-5-nitro-2-oxo-4-phenylpentanoate (**6aa**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 13.4$  min,  $t_2 = 30.3$  min) and the dr values were determined by  $^1\text{H}$  NMR to be >20:1 in all cases.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.17–7.25 (m, 4H), 7.10–7.17 (m, 4H), 7.04–7.06 (m, 2H), 4.66–4.77 (m, 2H), 4.12–4.18 (m, 1H), 3.83–3.89 (m, 1H), 2.90–2.92 (m, 2H), 1.20 (s, 9H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  196.4, 159.2, 137.1, 136.8, 129.1, 129.0, 128.8, 128.2, 128.2, 127.0, 84.2, 77.7, 50.8, 45.6, 35.9, 27.5. HRMS (ESI) Calcd. for  $\text{C}_{22}\text{H}_{25}\text{NO}_5$   $[\text{M}+\text{Na}]^+$ : 406.1625; Found: 406.1621. **Method a**: 63 mg, 82% yield, 91% ee,  $[\alpha]_{\text{D}}^{20} = -28.1$  (c 0.40,  $\text{CHCl}_3$ ); **Method b**: 68 mg, 89% yield, -89% ee,  $[\alpha]_{\text{D}}^{20} = +24.2$  (c 0.52,  $\text{CHCl}_3$ ); **Method c**: 71 mg, 93% yield, -92% ee,  $[\alpha]_{\text{D}}^{20} = +30.1$  (c 0.67,  $\text{CHCl}_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-(4-methylbenzyl)-5-nitro-2-oxo-4-phenylpentanoate (**6ba**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (90:10 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 26.2$  min,  $t_2 = 40.3$  min) and the dr value were determined by  $^1\text{H}$  NMR to be > 20:1 in all cases.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.20–7.31 (m, 5H), 6.99–7.07 (m, 4H), 4.70–4.82 (m, 2H), 4.16–4.22 (m, 1H), 3.89–3.95 (m, 1H), 2.94–2.96 (m, 2H), 2.28 (s, 3H), 1.28 (s, 9H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  196.5, 159.3, 136.9, 136.6, 133.9, 129.5, 129.0, 128.8, 128.2,

84.1, 77.8, 50.9, 45.6, 35.5, 27.4, 21.0. HRMS (ESI) Calcd. for  $C_{23}H_{27}NO_5$   $[M+Na]^+$ : 420.1781; Found: 420.1786. Method **a**: 50 mg, 63% yield, 89% ee,  $[\alpha]_D^{20} = -30.0$  (*c* 0.30,  $CHCl_3$ ); Method **b**: 51 mg, 64% yield, -80% ee,  $[\alpha]_D^{20} = +31.0$  (*c* 0.26,  $CHCl_3$ ); Method **c**: 65 mg, 82% yield, -91% ee,  $[\alpha]_D^{20} = +32.3$  (*c* 0.34,  $CHCl_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-(3,4-dichlorobenzyl)-5-nitro-2-oxo-4-phenylpentanoate (**6ca**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (80:20 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 15.9$  min,  $t_2 = 18.7$  min) and the dr values were determined by  $^1H$  NMR to be >20:1 in all cases.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  7.26–7.34 (m, 4H), 7.20–7.22 (m, 3H), 6.92–6.95 (m, 1H), 4.79–4.80 (m, 2H), 4.14–4.20 (m, 1H), 3.90–3.95 (m, 1H), 2.94 (d, *J* = 8.0 Hz, 2H), 1.32 (s, 9H).  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  195.9, 159.3, 137.4, 136.3, 132.7, 131.1, 130.9, 130.7, 129.2, 128.5, 128.4, 128.1, 84.6, 77.4, 50.7, 45.5, 34.5, 27.4. HRMS (ESI) Calcd. for  $C_{22}H_{23}Cl_2NO_5$   $[M+Na]^+$ : 474.0845; Found: 474.0848. Method **a**: 55 mg, 61% yield, 66% ee,  $[\alpha]_D^{20} = -10.4$  (*c* 0.26,  $CHCl_3$ ); Method **b**: 61 mg, 68% yield, -86% ee,  $[\alpha]_D^{20} = +13.8$  (*c* 0.61,  $CHCl_3$ ); Method **c**: 73 mg, 81% yield, -92% ee,  $[\alpha]_D^{20} = +12.0$  (*c* 0.45,  $CHCl_3$ ).

(*R*)-*tert*-Butyl-3-((*R*)-2-nitro-1-phenylethyl)-2-oxo-6-phenylhexanoate (**6da**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the products were determined by HPLC using a Chiralcel OD-H column (95:5 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 23.5$  min,  $t_2 = 26.9$  min) and the dr values were determined by  $^1H$  NMR to be >20:1 in all cases.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  7.24–7.31 (m, 5H), 7.15–7.20 (m, 3H), 7.10–7.12 (m, 2H), 4.63–4.65 (m, 2H), 3.73–3.84 (m, 2H), 2.53–2.65 (m, 2H), 1.77–1.87 (m, 1H), 1.51–1.66 (m, 3H), 1.39 (s, 9H).  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  196.6, 160.3, 141.2, 136.9, 129.1, 128.5, 128.4, 128.1, 126.1, 84.4, 77.6, 49.6, 45.2, 35.5, 28.5, 28.4, 27.6. HRMS (ESI) Calcd. for  $C_{24}H_{29}NO_5$   $[M+Na]^+$ : 434.1938; Found: 434.1947. Method **a**: 35 mg, 43% yield, 88% ee,  $[\alpha]_D^{20} = -15.1$  (*c* 0.25,  $CHCl_3$ ); Method **b**: 68 mg, 83% yield, -84% ee,  $[\alpha]_D^{20} = +13.2$  (*c* 0.59,  $CHCl_3$ ); Method **c**: 58 mg, 71% yield, -91% ee,  $[\alpha]_D^{20} = +15.5$  (*c* 0.41,  $CHCl_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-5-nitro-2-oxo-4-*p*-tolylpentanoate (**6ab**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the products were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 11.3$  min,  $t_2 = 24.5$  min) and the dr values were determined by  $^1H$  NMR to be >20:1 in all cases.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  7.17–7.27 (m, 3H), 7.09–7.13 (m, 6H), 4.70–4.81 (m, 2H), 4.16–4.22 (m, 1H), 3.85–3.91 (m, 1H), 2.99 (d, *J* = 7.6 Hz, 2H), 2.28 (s, 3H), 1.28 (s, 9H).  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  196.5, 159.3, 137.9, 137.2, 133.6, 129.8, 129.0, 128.8, 128.0, 126.9, 84.1, 77.9, 50.9, 45.4, 35.9, 27.4, 21.1. HRMS (ESI) Calcd. for  $C_{23}H_{27}NO_5$   $[M+Na]^+$ : 420.1781; Found: 420.1771. Method **a**: 36 mg, 44% yield, 91% ee,  $[\alpha]_D^{20} = -18.8$  (*c* 0.17,  $CHCl_3$ ); Method **b**:

49 mg, 62% yield, -86% ee,  $[\alpha]_D^{20} = +19.6$  (*c* 0.28,  $CHCl_3$ ); Method **c**: 72 mg, 91% yield, -92% ee,  $[\alpha]_D^{20} = +22.1$  (*c* 0.38,  $CHCl_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(4-methoxyphenyl)-5-nitro-2-oxopentanoate (**6ac**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 14.4$  min,  $t_2 = 32.2$  min) and the dr values were determined by  $^1H$  NMR to be >20:1 in all cases.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  7.17–7.27 (m, 3H), 7.11–7.14 (m, 4H), 6.82 (d, *J* = 8.4 Hz, 2H), 4.67–4.80 (m, 2H), 4.15–4.21 (m, 1H), 3.83–3.89 (m, 1H), 3.75 (s, 3H), 2.98 (d, *J* = 8.0 Hz, 2H), 1.28 (s, 9H).  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  196.6, 159.3, 159.2, 137.2, 129.3, 129.0, 128.8, 128.5, 126.9, 114.4, 84.1, 78.1, 55.2, 50.9, 45.1, 36.0, 27.5. HRMS (ESI) Calcd. for  $C_{23}H_{27}NO_6$   $[M+Na]^+$ : 436.1731; Found: 436.1721. Method **a**: 53 mg, 64% yield, 86% ee,  $[\alpha]_D^{20} = -26.9$  (*c* 0.30,  $CHCl_3$ ); Method **b**: 52 mg, 63% yield, -80% ee,  $[\alpha]_D^{20} = +26.3$  (*c* 0.41,  $CHCl_3$ ); Method **c**: 71 mg, 86% yield, -92% ee,  $[\alpha]_D^{20} = +28.7$  (*c* 0.55,  $CHCl_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(4-fluorophenyl)-5-nitro-2-oxopentanoate (**6ad**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 11.7$  min,  $t_2 = 32.8$  min) and the dr values were determined by  $^1H$  NMR to be >20:1 in all cases.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  7.18–7.29 (m, 5H), 7.11–7.13 (m, 2H), 6.97–7.01 (m, 2H), 4.78–4.83 (m, 1H), 4.68–4.74 (m, 1H), 4.17–4.24 (m, 1H), 3.88–3.94 (m, 1H), 2.96–2.99 (m, 2H), 1.28 (s, 9H).  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  196.4, 163.6, 161.2, 159.3, 136.8, 132.5, 132.4, 130.0, 129.9, 129.0, 128.9, 127.1, 116.1, 115.9, 84.3, 77.9, 50.6, 45.0, 36.1, 27.5;  $^{19}F$  NMR (376 MHz,  $CDCl_3$ ): -113.5. HRMS (ESI) Calcd. for  $C_{22}H_{24}FNO_5$   $[M+Na]^+$ : 424.1531; Found: 424.1520. Method **a**: 28 mg, 35% yield, 87% ee,  $[\alpha]_D^{20} = -35.4$  (*c* 0.44,  $CHCl_3$ ); Method **b**: 59 mg, 74% yield, -90% ee,  $[\alpha]_D^{20} = +35.6$  (*c* 0.44,  $CHCl_3$ ); Method **c**: 64 mg, 80% yield, -91% ee,  $[\alpha]_D^{20} = +34.3$  (*c* 0.26,  $CHCl_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(4-chlorophenyl)-5-nitro-2-oxopentanoate (**6ae**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 13.4$  min,  $t_2 = 33.9$  min) and the dr values were determined by  $^1H$  NMR to be >20:1 in all cases.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  7.25–7.29 (m, 4H), 7.15–7.23 (m, 3H), 7.11–7.13 (m, 2H), 4.78–4.82 (m, 1H), 4.68–4.74 (m, 1H), 4.17–4.23 (m, 1H), 3.87–3.93 (m, 1H), 2.96–2.98 (m, 2H), 1.29 (s, 9H).  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  196.3, 159.3, 136.7, 135.3, 134.2, 129.6, 129.3, 129.0, 128.9, 127.1, 84.4, 77.7, 50.5, 45.1, 36.0, 27.5. HRMS (ESI) Calcd. for  $C_{22}H_{24}ClNO_5$   $[M+Na]^+$ : 440.1235; Found: 440.1234. Method **a**: 32 mg, 38% yield, 92% ee,  $[\alpha]_D^{20} = -26.2$  (*c* 0.21,  $CHCl_3$ ); Method **b**: 40 mg, 48% yield, -91% ee,  $[\alpha]_D^{20} = +25.9$  (*c* 0.28,  $CHCl_3$ ); Method **c**: 65 mg, 78% yield,

–92% ee,  $[\alpha]_{\text{D}}^{20} = +27.9$  (*c* 0.47,  $\text{CHCl}_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(4-bromophenyl)-5-nitro-2-oxopentanoate (**6af**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 14.8$  min,  $t_2 = 36.6$  min) and the dr values were determined by  $^1\text{H}$  NMR to be >20:1 in all cases.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.41–7.44 (m, 2H), 7.19–7.29 (m, 3H), 7.09–7.13 (m, 4H), 4.68–4.82 (m, 2H), 4.17–4.23 (m, 1H), 4.17–4.23 (m, 1H), 3.86–3.91 (m, 1H), 2.96–2.98 (m, 2H), 1.29 (s, 9H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  196.2, 159.3, 136.7, 135.8, 132.2, 129.9, 129.0, 128.9, 127.1, 122.4, 84.4, 77.6, 50.4, 45.1, 36.0, 27.4. HRMS (ESI) Calcd. for  $\text{C}_{22}\text{H}_{24}\text{BrNO}_5$   $[\text{M}+\text{Na}]^+$ : 484.0730; Found: 484.0729. Method **a**: 56 mg, 61% yield, 94% ee,  $[\alpha]_{\text{D}}^{20} = -20.9$  (*c* 0.28,  $\text{CHCl}_3$ ); Method **b**: 78 mg, 84% yield, –94% ee,  $[\alpha]_{\text{D}}^{20} = +21.6$  (*c* 0.25,  $\text{CHCl}_3$ ); Method **c**: 76 mg, 82% yield, –93% ee,  $[\alpha]_{\text{D}}^{20} = +20.3$  (*c* 0.48,  $\text{CHCl}_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(3-chlorophenyl)-5-nitro-2-oxopentanoate (**6ag**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 13.6$  min,  $t_2 = 34.1$  min) and the dr values were determined by  $^1\text{H}$  NMR to be >20:1 in all cases.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.25–7.29 (m, 4H), 7.15–7.23 (m, 3H), 7.11–7.13 (m, 2H), 4.68–4.82 (m, 2H), 4.17–4.23 (m, 1H), 3.87–3.93 (m, 1H), 2.96–2.98 (m, 2H), 1.28 (s, 9H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  196.3, 159.3, 136.7, 135.3, 134.2, 129.6, 129.3, 129.0, 128.9, 127.1, 84.4, 77.7, 50.5, 45.1, 36.0, 27.5. HRMS (ESI) Calcd. for  $\text{C}_{22}\text{H}_{24}\text{ClNO}_5$   $[\text{M}+\text{Na}]^+$ : 440.1235; Found: 440.1235. Method **a**: 46 mg, 55% yield, 91% ee,  $[\alpha]_{\text{D}}^{20} = -24.4$  (*c* 0.27,  $\text{CHCl}_3$ ); Method **b**: 72 mg, 86% yield, –84% ee,  $[\alpha]_{\text{D}}^{20} = +26.0$  ( $\text{CHCl}_3$ , *c* 0.36); Method **c**: 75 mg, 90% yield, –93% ee,  $[\alpha]_{\text{D}}^{20} = +26.5$  (*c* 0.37,  $\text{CHCl}_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(2-bromophenyl)-5-nitro-2-oxopentanoate (**6ah**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 10.0$  min,  $t_2 = 21.0$  min) and the dr values were determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.61–7.63 (m, 0.09H), 7.56–7.58 (m, 0.91H), 7.02–7.31 (m, 8H), 4.88–4.93 (m, 1H), 4.81–4.85 (m, 1H), 4.40–4.52 (m, 2H), 3.12–3.17 (m, 1H), 2.90–2.96 (m, 1H), 1.31 (s, 0.83H), 1.25 (s, 8.4H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  196.9, 159.3, 136.7, 136.1, 134.0, 129.7, 129.1, 129.0, 128.8, 128.7, 128.2, 127.9, 127.0, 124.9, 84.6, 84.2, 77.4, 48.8, 44.0, 36.2, 27.5, 27.5. HRMS (ESI) Calcd. for  $\text{C}_{22}\text{H}_{24}\text{BrNO}_5$   $[\text{M}+\text{Na}]^+$ : 484.0730; Found: 484.0725. Method **a**: 65 mg, 70% yield, 63% ee, dr = 6:4,  $[\alpha]_{\text{D}}^{20} = -30.4$  (*c* 0.35,  $\text{CHCl}_3$ ); Method **b**: 76 mg, 82% yield, –90% ee, dr = 10:1,  $[\alpha]_{\text{D}}^{20} = +66.7$  (*c* 0.60,  $\text{CHCl}_3$ ); Method **c**: 78 mg, 84% yield, –83% ee, dr = 10:1,  $[\alpha]_{\text{D}}^{20} = +56.6$  (*c* 0.76,  $\text{CHCl}_3$ ).

(3*R*,4*R*)-*tert*-Butyl-3-benzyl-4-(naphthalen-1-yl)-5-nitro-2-

oxopentanoate (**6ai**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (70:30 hexane:isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 16.3$  min,  $t_2 = 29.8$  min) and the dr values were determined by  $^1\text{H}$  NMR to be >20:1 in all three cases.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.16 (d, *J* = 8.0 Hz, 1H), 7.78 (d, *J* = 8.4 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.51–7.55 (m, 1H), 7.41–7.45 (m, 1H), 7.36–7.38 (m, 1H), 7.29–7.32 (m, 1H), 7.06–7.16 (m, 3H), 6.96–6.98 (m, 2H), 4.81–4.87 (m, 3H), 4.37 (br, s, 1H), 2.92–3.03 (m, 2H), 1.14 (s, 9H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  196.6, 159.4, 137.2, 134.3, 133.2, 131.1, 129.2, 129.0, 128.7, 127.1, 126.9, 126.2, 125.0, 124.6, 122.7, 84.2, 76.2, 50.7, 35.7, 27.4. HRMS (ESI) Calcd. for  $\text{C}_{26}\text{H}_{27}\text{NO}_5$   $[\text{M}+\text{Na}]^+$ : 456.1781; Found: 456.1775. Method **a**: 70 mg, 81% yield, 66% ee,  $[\alpha]_{\text{D}}^{20} = -50.0$  (*c* 0.28,  $\text{CHCl}_3$ ); Method **b**: 69 mg, 80% yield, –84% ee,  $[\alpha]_{\text{D}}^{20} = +78.7$  (*c* 0.32,  $\text{CHCl}_3$ ); Method **c**: 82 mg, 95% yield, –90% ee,  $[\alpha]_{\text{D}}^{20} = +89.9$  (*c* 0.69,  $\text{CHCl}_3$ ).

(3*R*,4*S*)-*tert*-Butyl-3-benzyl-4-(furan-2-yl)-5-nitro-2-oxopentanoate (**6aj**). The title compound was prepared according to the general procedures described above and purified by column chromatography to give a white solid. The ee values of the product were determined by HPLC using a Chiralcel OD-H column (90:10 hexane: isopropanol, 1 mL/min, 254 nm, 25 °C;  $t_1 = 16.8$  min,  $t_2 = 33.6$  min) and the dr values were determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.37–7.38 (m, 0.16H), 7.34–7.35 (m, 0.84H), 7.18–7.29 (m, 3H), 7.12–7.14 (m, 1.75H), 7.07–7.09 (m, 0.33H), 6.31–6.32 (m, 0.16H), 6.28–6.30 (m, 0.84H), 6.24 (d, *J* = 3.2 Hz, 0.15H), 6.21 (d, *J* = 3.2 Hz, 0.84H), 4.75–4.78 (m, 2H), 4.03–4.18 (m, 2H), 2.71–3.00 (m, 2H), 1.39 (s, 7.46H), 1.37 (s, 1.59H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  197.2, 195.8, 160.0, 159.4, 150.0, 149.9, 142.8, 142.7, 137.2, 136.8, 129.1, 129.0, 128.8, 128.8, 127.0, 126.9, 110.6, 110.5, 109.2, 108.7, 84.6, 84.5, 75.9, 75.4, 49.4, 49.3, 39.0, 38.9, 36.6, 35.0, 27.6. HRMS (ESI) Calcd. for  $\text{C}_{20}\text{H}_{23}\text{NO}_6$   $[\text{M}+\text{Na}]^+$ : 396.1418; Found: 396.1402. Method **a**: 45 mg, 60% yield, 92% ee, dr = 7:3,  $[\alpha]_{\text{D}}^{20} = -1.8$  (*c* 0.17,  $\text{CHCl}_3$ ); Method **b**: 53 mg, 71% yield, –85% ee, dr = 7:1,  $[\alpha]_{\text{D}}^{20} = +4.7$  (*c* 0.42,  $\text{CHCl}_3$ ); Method **c**: 60 mg, 80% yield, –93% ee, dr = 5.25:1 (the dr value can be calculated from the  $^1\text{H}$  NMR using the ratio of the integral belonging to the signal at  $\delta = 7.34$ –7.35 (m, 0.84H) and those at  $\delta = 7.37$ –7.38 (m, 0.16H),  $\delta = 6.31$ –6.32 (m, 0.16H) and  $\delta = 6.28$ –6.30 (m, 0.84H), or the ratio of the integral belonging to the signal at  $\delta = 6.24$  (d, *J* = 3.2 Hz, 0.15H) to that at  $\delta = 6.21$  (d, *J* = 3.2 Hz, 0.84H)),  $[\alpha]_{\text{D}}^{20} = +2.2$  (*c* 0.45,  $\text{CHCl}_3$ ).

### 3. Results and discussion

The reaction of  $\alpha$ -keto ester **4a** with nitrostyrene **5a** was initially evaluated under a variety of previously published conditions for the asymmetric formal [2+2] cyclization reaction [50]. The use of  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}/\mathbf{2a}$  as a catalytic system at room temperature afforded the desired product **6aa** in 80% yield with 88% ee. Several different ligands bearing a variety of different halo substituents were evaluated to determine the impact of different structural and electronic features on the out-

come of the reaction. Among the fluoro-(**2b**), chloro-(**2c**) and bromo-(**2d**) substituted diamines, the fluoro-substituted diamine ligand **2b** exhibited the highest efficiency and gave the desired product in 82% yield with 91% ee, as well as a distereoselectivity of 20:1 (Table 1, entry 2). Notably, the replacement of the metal precursor with Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O gave the desired product but with a reversal in the enantioselectivity (74% ee, Table 1, entry 5) under otherwise identical conditions. Furthermore, this reversal in the enantioselectivity was improved to 89% ee using Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O/**2d** as the catalyst with CPME as the solvent (Table 1, entry 14). The enantioselectivity was also reversed when ligand **2** was replaced by the more rigid ligand **3**, even though Cu(OAc)<sub>2</sub>·H<sub>2</sub>O was used as the metal source in both cases. Pleasingly, the loading of the Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/**3** catalyst could be reduced to 1 mol% without an appreciable drop-off in the reactivity of the substrates or the enantioselectivity of the product, which was formed in 93% yield and 92% ee with the antipodal configuration (Table 1, entry 16). However, no switch was observed in the enantioselectivity when Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O was used in conjunction with the rigid ligand **3** (Table 1, entry 17). These results therefore demonstrate that both enantiomers of the desired product


could be obtained with excellent levels of enantioselectivity by tuning the metal center or the rigidity of the ligand.

Having established the optimal conditions for the catalytic conjugate addition reaction, in terms of the metal and ligand combination systems, we proceeded to investigate the substrate scope of this transformation. A variety of synthetically useful  $\alpha$ -keto esters and nitroalkenes bearing different functionalities were well tolerated under the optimized conditions, with excellent levels of stereoselectivity being observed in the majority of cases (Table 2). The initial part of this study focused on the reactions catalyzed by Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/**2b**. As shown in Table 2,  $\alpha$ -keto esters containing an electron-rich phenyl ring and a long chain alkyl group demonstrated good reactivity to give the corresponding adducts with high enantioselectivities (Table 2, **6ba** and **6da**, 89% and 88% ee, respectively). In contrast,  $\alpha$ -keto ester **4c** bearing an electron-deficient phenyl ring gave a much lower enantioselectivity of 66% ee under the same conditions. The conjugate reaction was also tolerant of aromatic nitroalkenes bearing a range of different substituents. Several substituted aromatic nitroalkenes (**5a–g**) bearing an electron-donating or electron-withdrawing group at the *para* or *meta* position of their phenyl ring also reacted smoothly under the optimized conditions to give the corresponding addition products **6ab–ag** in moderate to high yields with excellent enantioselectivities and complete diastereoselectivity. Nitroalkenes **5h** and **5i** bearing substituents at the *ortho* position of their phenyl ring reacted smoothly to give the desired products in good yields, although the enantioselectivities observed in these reactions were low (i.e., 63% and 66% ee) because of steric hindrance from the *ortho*-substituents. 2-Furyl-nitroalkene was also well tolerated under the optimized reaction conditions and gave the desired product in 60% yield with 92% ee, although the diastereoselectivity was low in this case (dr = 7:3).

The catalytic ability of Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O/**2d** was also investigated, with the corresponding antipodal enantiomers being obtained with high enantioselectivities and excellent levels of diastereoselectivity (up to 94% ee and >20:1 dr). In contrast to Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/**2b**, the enantioselectivity of the reaction catalyzed by Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O/**2d** appeared to be insensitive to the steric or electronic properties of the substituents on the phenyl ring (**6aa–ai**, 80%–94% ee, 10:1–20:1 dr). This apparent lack of sensitivity to these factors could be attributed to differences in the coordinate modes of the two metals. The 2-furyl-nitroalkene **5j** also reacted with  $\alpha$ -keto ester **4a** in the presence of the Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O/**2d** catalyst to give the corresponding addition product in 71% yield with 85% ee and a diastereoselectivity of 7:1.

The conjugate addition of  $\alpha$ -keto esters to nitroalkenes was also investigated in the presence of 1 mol% of the Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/**3** catalyst under the optimized reaction conditions. Compared to the ligand **2** (BIDN) derived catalytic system, the rigid six-membered ring of the diamine **3** ligated Cu-catalyst showed stronger chiral induction ability and higher reactivity. All of the reactions conducted in the presence of the Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/**3** catalyst proceeded smoothly to give the desired products in high isolated yields (**6aa–ai**, 78%–93%). A reversal was achieved in the absolute configuration of the

**Table 1**  
Screening of the reaction conditions.<sup>a</sup>



Entry	Catalyst	Solvent	<b>6aa</b>	
			Yield <sup>b</sup> (%)	ee (%)
1	Cu(OAc) <sub>2</sub> ·H <sub>2</sub> O/ <b>2a</b>	<i>i</i> -PrOH	80	88 ( <i>S,S</i> )
2	Cu(OAc) <sub>2</sub> ·H <sub>2</sub> O/ <b>2b</b>	<i>i</i> -PrOH	82	91 ( <i>S,S</i> )
3	Cu(OAc) <sub>2</sub> ·H <sub>2</sub> O/ <b>2c</b>	<i>i</i> -PrOH	51	82 ( <i>S,S</i> )
4	Cu(OAc) <sub>2</sub> ·H <sub>2</sub> O/ <b>2d</b>	<i>i</i> -PrOH	59	85 ( <i>S,S</i> )
5	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2b</b>	<i>i</i> -PrOH	91	74 ( <i>R,R</i> )
6 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2a</b>	<i>i</i> -PrOH	90	68 ( <i>R,R</i> )
7 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2a</b>	CPME	65	82 ( <i>R,R</i> )
8 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2a</b>	Et <sub>2</sub> O	66	82 ( <i>R,R</i> )
9 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2a</b>	THF	91	79 ( <i>R,R</i> )
10 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2a</b>	PhCH <sub>3</sub>	84	77 ( <i>R,R</i> )
11 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2b</b>	CPME	65	87 ( <i>R,R</i> )
12 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2c</b>	CPME	80	85 ( <i>R,R</i> )
13 <sup>c</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2d</b>	CPME	64	88 ( <i>R,R</i> )
14 <sup>c,d</sup>	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>2d</b>	CPME	89	89 ( <i>R,R</i> )
15	Cu(OAc) <sub>2</sub> ·H <sub>2</sub> O/ <b>3</b>	<i>i</i> -PrOH	89	93 ( <i>R,R</i> )
16 <sup>e</sup>	Cu(OAc) <sub>2</sub> ·H <sub>2</sub> O/ <b>3</b>	<i>i</i> -PrOH	93	92 ( <i>R,R</i> )
17	Ni(OAc) <sub>2</sub> ·4H <sub>2</sub> O/ <b>3</b>	<i>i</i> -PrOH	95	78 ( <i>R,R</i> )

<sup>a</sup> Reaction conditions: **4a** (0.22 mmol), **5a** (0.20 mmol), [MXn] 5 mol%, ligand 5.5 mol%, and Et<sub>3</sub>N 5 mol% stirred in solvent (2.0 mL) at room temperature for 10 h, unless otherwise noted; the ee values were determined by HPLC analysis using a chiral stationary phase.

<sup>b</sup> Isolated yield, the dr values were determined to be > 20:1 in all cases.


<sup>c</sup> The reaction was stirred for 16 h.

<sup>d</sup> **4a** (0.30 mmol) and **5a** (0.20 mmol) were used in the reaction.

<sup>e</sup> [MXn] 1 mol% and **3** 1.1 mol% were used in the reaction.

**Table 2**

Catalytic asymmetric conjugate addition of various  $\alpha$ -keto esters to nitroalkenes.



Entry	R	Ar	Yield <sup>b</sup> (%)	ee (%)	dr
1 <sup>a</sup>	PhCH <sub>2</sub>	Ph	<b>6aa</b> (82)	91	>20:1
2 <sup>b,d</sup>	PhCH <sub>2</sub>	Ph	<b>6aa</b> (89)	-89	>20:1
3 <sup>c</sup>	PhCH <sub>2</sub>	Ph	<b>6aa</b> (93)	-92	>20:1
4 <sup>a</sup>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	Ph	<b>6ba</b> (63)	89	>20:1
5 <sup>b</sup>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	Ph	<b>6ba</b> (64)	-80	>20:1
6 <sup>c</sup>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>	Ph	<b>6ba</b> (82)	-91	>20:1
7 <sup>a</sup>	3,4-bis(Cl)C <sub>6</sub> H <sub>3</sub> CH <sub>2</sub>	Ph	<b>6ca</b> (61)	66	>20:1
8 <sup>b</sup>	3,4-bis(Cl)C <sub>6</sub> H <sub>3</sub> CH <sub>2</sub>	Ph	<b>6ca</b> (68)	-86	>20:1
9 <sup>c</sup>	3,4-bis(Cl)C <sub>6</sub> H <sub>3</sub> CH <sub>2</sub>	Ph	<b>6ca</b> (81)	-92	>20:1
10 <sup>a</sup>	Ph(CH <sub>2</sub> ) <sub>3</sub>	Ph	<b>6da</b> (43)	88	>20:1
11 <sup>b</sup>	Ph(CH <sub>2</sub> ) <sub>3</sub>	Ph	<b>6da</b> (83)	-84	>20:1
12 <sup>c</sup>	Ph(CH <sub>2</sub> ) <sub>3</sub>	Ph	<b>6da</b> (71)	-91	>20:1
13 <sup>a</sup>	PhCH <sub>2</sub>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>6ab</b> (44)	91	>20:1
14 <sup>b</sup>	PhCH <sub>2</sub>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>6ab</b> (62)	-86	>20:1
15 <sup>c</sup>	PhCH <sub>2</sub>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>6ab</b> (91)	-92	>20:1
16 <sup>a</sup>	PhCH <sub>2</sub>	<i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	<b>6ac</b> (64)	86	>20:1
17 <sup>b</sup>	PhCH <sub>2</sub>	<i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	<b>6ac</b> (63)	-80	>20:1
18 <sup>c</sup>	PhCH <sub>2</sub>	<i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	<b>6ac</b> (86)	-92	>20:1
19 <sup>a</sup>	PhCH <sub>2</sub>	<i>p</i> -FC <sub>6</sub> H <sub>4</sub>	<b>6ad</b> (35)	87	>20:1
20 <sup>b,d</sup>	PhCH <sub>2</sub>	<i>p</i> -FC <sub>6</sub> H <sub>4</sub>	<b>6ad</b> (74)	-90	>20:1
21 <sup>c</sup>	PhCH <sub>2</sub>	<i>p</i> -FC <sub>6</sub> H <sub>4</sub>	<b>6ad</b> (80)	-91	>20:1
22 <sup>a</sup>	PhCH <sub>2</sub>	<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	<b>6ae</b> (38)	92	>20:1
23 <sup>b,d</sup>	PhCH <sub>2</sub>	<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	<b>6ae</b> (48)	-91	>20:1
24 <sup>c</sup>	PhCH <sub>2</sub>	<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	<b>6ae</b> (78)	-92	>20:1
25 <sup>a</sup>	PhCH <sub>2</sub>	<i>p</i> -BrC <sub>6</sub> H <sub>4</sub>	<b>6af</b> (61)	94	>20:1
26 <sup>b</sup>	PhCH <sub>2</sub>	<i>p</i> -BrC <sub>6</sub> H <sub>4</sub>	<b>6af</b> (84)	-94	>20:1
27 <sup>c</sup>	PhCH <sub>2</sub>	<i>p</i> -BrC <sub>6</sub> H <sub>4</sub>	<b>6af</b> (82)	-93	>20:1
28 <sup>a</sup>	PhCH <sub>2</sub>	3-ClC <sub>6</sub> H <sub>4</sub>	<b>6ag</b> (55)	91	>20:1
29 <sup>b,d</sup>	PhCH <sub>2</sub>	3-ClC <sub>6</sub> H <sub>4</sub>	<b>6ag</b> (86)	-84	>20:1
30 <sup>c</sup>	PhCH <sub>2</sub>	3-ClC <sub>6</sub> H <sub>4</sub>	<b>6ag</b> (90)	-93	>20:1
31 <sup>a</sup>	PhCH <sub>2</sub>	<i>o</i> -BrC <sub>6</sub> H <sub>4</sub>	<b>6ah</b> (70)	63	6:4
32 <sup>b</sup>	PhCH <sub>2</sub>	<i>o</i> -BrC <sub>6</sub> H <sub>4</sub>	<b>6ah</b> (82)	-90	10:1
33 <sup>c</sup>	PhCH <sub>2</sub>	<i>o</i> -BrC <sub>6</sub> H <sub>4</sub>	<b>6ah</b> (84)	-83	10:1
34 <sup>a</sup>	PhCH <sub>2</sub>	2-naphthyl	<b>6ai</b> (81)	66	>20:1
35 <sup>b</sup>	PhCH <sub>2</sub>	2-naphthyl	<b>6ai</b> (80)	-84	>20:1
36 <sup>c</sup>	PhCH <sub>2</sub>	2-naphthyl	<b>6ai</b> (95)	-90	>20:1
37 <sup>a</sup>	PhCH <sub>2</sub>	2-furanyl	<b>6aj</b> (60)	92	7:3
38 <sup>b</sup>	PhCH <sub>2</sub>	2-furanyl	<b>6aj</b> (71)	-85	7:1
39 <sup>c</sup>	PhCH <sub>2</sub>	2-furanyl	<b>6aj</b> (80)	-93	5.25:1

<sup>a</sup> Method **a**: ketoester (0.22 mmol), nitrosytrene (0.20 mmol), Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/(*S,S*)-**2b** (0.01 mmol, 5 mol%) and Et<sub>3</sub>N (1.5  $\mu$ L, 5 mol%) stirred in 2-PrOH (2.0 mL) at room temperature for 10 h.

<sup>b</sup> Method **b**: ketoester (0.22 mmol), nitrosytrene (0.20 mmol), Ni(OAc)<sub>2</sub>·4H<sub>2</sub>O/(*S,S*)-**2d** (0.01 mmol, 5 mol%) and Et<sub>3</sub>N (1.5  $\mu$ L, 5 mol%) stirred in CPME (2.0 mL) at room temperature for 16 h.

<sup>c</sup> Method **c**: ketoester (0.22 mmol), nitrosytrene (0.20 mmol), Cu(OAc)<sub>2</sub>·H<sub>2</sub>O/(*S,S*)-**3** (0.002 mmol, 1 mol%) and Et<sub>3</sub>N (1.5  $\mu$ L, 5 mol%) in *i*-PrOH (2.0 mL) at room temperature for 10 h.

<sup>d</sup> 1.5 equiv of the  $\alpha$ -ketoester was added.

products resulting from the reactions of various  $\alpha$ -keto esters and nitroalkenes regardless of the steric hindrance and electronic properties of the phenyl ring on the nitroalkene substrates (**6aa–ai**, 83%–93% ee, 10:1–20:1 dr). The heteroaromatic nitroalkene **5j** was also examined under the same conditions, and gave the corresponding product in **6aj** in 80% yield,

93% ee and a diastereoselectivity of 5.25:1 with a reversal in the absolute configuration.

A detailed mechanistic explanation for the switch observed in the enantioselectivity during the asymmetric conjugate addition of  $\alpha$ -keto esters to nitroalkenes remains unclear at the present stage. One possible explanation for the observed metal-directed switching in the enantioselectivity of these reactions could be based on differences in the ionic radii, in that the Lewis acidity or coordination pattern between the Cu<sup>2+</sup> and Ni<sup>2+</sup> ions may have led to the formation of the corresponding enolate, which would have adopted a different geometry to that of the coordinated  $\alpha$ -keto esters [42,50]. Differences in the geometry of the active enolate could lead to the nitroalkene being attacked from the opposite direction during the conjugate addition reaction. This reaction would therefore give rise to the desired product but with the reverse enantioselectivity.

#### 4. Conclusions

We have developed an efficient catalytic system for the highly enantioselective and diastereoselective conjugate addition of  $\alpha$ -keto esters to nitroalkenes using chiral diamines as ligands. Dual enantioselective control was achieved with this method through the tuning of the metal center of the catalyst or the rigidity of the chiral diamine ligand. Both enantiomers of various addition products were prepared in this way with high enantioselectivity. The unique rigid structures of the chiral diamine ligands appeared to play a key role in the realization of this dual enantioselective control process.

#### References

- [1] Sibi M P, Liu M. *Curr Org Chem*, 2001, 5: 719
- [2] Kim Y H. *Acc Chem Res*, 2001, 34: 955
- [3] Zanoni G, Castronovo F, Franzini M, Vidari G, Giannini E. *Chem Soc Rev*, 2003, 32: 115
- [4] Tanaka T, Hayashi M. *Synthesis*, 2008: 3361
- [5] Bartók M. *Chem Rev*, 2010, 110: 1663
- [6] Escorihuela J, Burguete M I, Luis S V. *Chem Soc Rev*, 2013, 42: 5595
- [7] Kanai M, Koga K, Tomioka K. *J Chem Soc, Chem Commun*, 1993: 1248
- [8] Zhou J, Ye M C, Huang Z Z, Tang Y. *J Org Chem*, 2004, 69: 1309
- [9] Casey C P, Martins S C, Fagan M A. *J Am Chem Soc*, 2004, 126: 5585
- [10] Lutz F, Igarashi T, Kinoshita T, Asahina M, Tsukiyama K, Kawasaki T, Soai K. *J Am Chem Soc*, 2008, 130: 2956
- [11] Blackmond D G, Moran A, Hughes M, Armstrong A. *J Am Chem Soc*, 2010, 132: 7598
- [12] Sohtome Y, Tanaka S, Takada K, Yamaguchi T, Nagasawa K. *Angew Chem Int Ed*, 2010, 49: 9254
- [13] Moteki S A, Han J, Arimitsu S, Akakura M, Nakayama K, Maruoka K. *Angew Chem Int Ed*, 2012, 51: 1187
- [14] Feng X, Zhou Z, Zhou R, Zhou Q Q, Dong L, Chen Y C. *J Am Chem Soc*, 2012, 134: 19942
- [15] Hoarau O, Ait-Haddou H, Daran J C, Cramailère D, Balavoine G G A. *Organometallics*, 1999, 18: 4718
- [16] Ait-Haddou H, Hoarau O, Cramailère D, Pezet F, Daran J C, Balavoine G G A. *Chem Eur J*, 2004, 10: 699
- [17] Zeng W, Chen G Y, Zhou Y G, Li Y X. *J Am Chem Soc*, 2007, 129: 750
- [18] Wu W Q, Peng Q, Dong D X, Hou X L, Wu Y D. *J Am Chem Soc*, 2008,


## Graphical Abstract

*Chin. J. Catal.*, 2015, 36: 57–67 doi: 10.1016/S1872-2067(14)60199-6

**Diastereo- and enantioselective conjugate addition of  $\alpha$ -keto esters to nitroalkenes: Complete switch in the enantioselectivity by tuning the metal center or rigidity of the ligand**

Xiangning Chen, Han Zhou, Hanmin Huang\*

Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences



The dual enantioselectivity for the conjugate addition of  $\alpha$ -keto esters to nitroalkenes has been controlled through the development of an efficient series of catalytic systems. Both enantiomers of the addition products were obtained in good yields with high enantioselectivities by tuning the rigidity of the chiral ligand or metal center.

130: 9717

- [19] Mouri S, Chen Z H, Mitsunuma H, Furutachi M, Matsunaga S, Shibasaki M. *J Am Chem Soc*, 2010, 132: 1255
- [20] Shibata N, Yoshimura M, Yamada H, Arakawa R, Sakaguchi S. *J Org Chem*, 2012, 77: 4079
- [21] Sibi M P, Shay J J, Liu M, Jasperse C P. *J Am Chem Soc*, 1998, 120: 6615
- [22] Murakami M, Itami K, Ito Y. *J Am Chem Soc*, 1999, 121: 4130
- [23] Luna A P, Bonin M, Micouin L, Husson H P. *J Am Chem Soc*, 2002, 124: 12098
- [24] Kim H Y, Shih H J, Knabe W E, Oh K. *Angew Chem Int Ed*, 2009, 48: 7420
- [25] Kim H Y, Oh K S. *Org Lett*, 2009, 11: 5682
- [26] Okamoto M, Yamamoto Y, Sakaguchi S. *Chem Commun*, 2009: 7363
- [27] Shibata N, Okamoto M, Yamamoto Y, Sakaguchi S. *J Org Chem*, 2010, 75: 5707
- [28] Liu Y L, Shang D J, Zhou X, Zhu Y, Lin L L, Liu X H, Feng X M. *Org Lett*, 2010, 12: 180
- [29] Wang Z, Yang Z G, Chen D H, Liu X H, Lin L L, Feng X M. *Angew Chem Int Ed*, 2011, 50: 4928
- [30] Larock R C. *Comprehensive Organic Transformations: A Guide to Functional Group Preparations*. New York: VCH, 1989. 411
- [31] Ono N. *The Nitro Group in Organic Synthesis*. New York: Wiley-VCH, 2001
- [32] Raimondi W, Bonne D, Rodriguez J. *Angew Chem Int Ed*, 2012, 51: 40
- [33] Raimondi W, Bonne D, Rodriguez J. *Chem Commun*, 2012, 48: 6763
- [34] Juhl K, Gathergood N, Jørgensen K A. *Angew Chem Int Ed*, 2001, 40: 2995
- [35] Juhl K, Jørgensen K A. *J Am Chem Soc*, 2002, 124: 2420
- [36] Torii H, Nakadai M, Ishihara K, Satio S, Yamamoto H. *Angew Chem Int Ed*, 2004, 43: 1983
- [37] Terada M, Amagai K, Ando K, Kwon E, Ube H. *Chem Eur J*, 2011, 17:

9037

- [38] Lu G, Morimoto H, Matsunaga S, Shibasaki M. *Angew Chem Int Ed*, 2008, 47: 6847
- [39] Xu Y J, Lu G, Matsunaga S, Shibasaki M. *Angew Chem Int Ed*, 2009, 48: 3353
- [40] Suzuki S, Kitamura Y, Lectard S, Hamashima Y, Sodeoka M. *Angew Chem Int Ed*, 2012, 51: 4581
- [41] Nakamura A, Lectard S, Shimizu R, Hamashima Y, Sodeoka M. *Tetrahedron: Asymmetry*, 2010, 21: 1682
- [42] Nakamura A, Lectard S, Hashizume D, Hamashima Y, Sodeoka M. *J Am Chem Soc*, 2010, 132: 4036
- [43] Raimondi W, Baslé O, Constantieux T, Bonne D, Rodriguez J. *Adv Synth Catal*, 2012, 354: 563
- [44] Xu Y J, Matsunaga S, Shibasaki M. *Org Lett*, 2010, 12: 3246
- [45] Baslé O, Raimondi W, Duque M D M S, Bonne D, Constantieux T, Rodriguez J. *Org Lett*, 2010, 12: 5246
- [46] Raimondi W, Sanchez Duque M D M, Gouedranche S, Quintard A, Constantieux T, Bugaut X, Bonne D, Rodriguez J. *Synthesis*, 2013, 45: 1659
- [47] Zhu Q M, Huang H M, Shi D J, Shen Z Q, Xia C G. *Org Lett*, 2009, 11: 4536
- [48] Zhu Q M, Huang H M, Xia C G. *J Mol Catal (China)*, 2011, 25: 6
- [49] Zhu Q M, Shi D J, Xia C G, Huang H M. *Chem Eur J*, 2011, 17: 7760
- [50] Shi D J, Xie Y J, Zhou H, Xia C G, Huang H M. *Angew Chem Int Ed*, 2012, 51: 1248
- [51] Zhou H, Huang H M. *ChemCatChem*, 2013, 5: 2253
- [52] Jia Y X, Xie J H, Duan H F, Wang L X, Zhou Q L. *Org Lett*, 2006, 8: 1621

Page numbers refer to the contents in the print version, which include both the English and Chinese versions of the paper. The online version only has the English version. The pages with the Chinese version are only available in the print version.